Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Gainers
- GeoVax Labs, Inc.. (NASDAQ:GOVX) shares rose 72.1% to $7.40 in pre-market trading after the company announced it presented COVID-19 vaccine data at the European Society of Medicine General Assembly.
- InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) rose 33.6% to $0.89 in pre-market trading after surging 12% on Thursday.
- Marin Software Incorporated (NASDAQ:MRIN) shares rose 32.6% to $6.38 in pre-market trading after the company disclosed an integration with Criteo's Commerce Media Platform.
- Marker Therapeutics, Inc. (NASDAQ:MRKR) rose 16.7% to $1.96 in pre-market trading after the company announced it was awarded a $13.1 million grant from the Cancer Prevention and Research Institute of Texas.
- TherapeuticsMD, Inc. (NASDAQ:TXMD) rose 15.8% to $0.88 in pre-market trading. TherapeuticsMD's Cooper C. Collins bought 1 million shares of the company’s common stock at an average price of $0.72 per share.
- Naked Brand Group Limited (NASDAQ:NAKD) rose 12.8% to $0.5661 in pre-market trading.
- FibroGen, Inc. (NASDAQ:FGEN) rose 9.1% to $12.51 in pre-market trading. Astellas Pharma and FibroGen, said the European Commission has approved EVRENZO™ (roxadustat) for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease (CKD).
- G Medical Innovations Holdings Ltd (NASDAQ:GMVD) shares rose 8.3% to $2.75 in pre-market trading after gaining 10% on Thursday.
- Zosano Pharma Corporation (NASDAQ:ZSAN) rose 5.8% to $0.64 in pre-market trading. The company, last week, posted a loss for the second quarter.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
Check out these big penny stock gainers and losers
Losers
- Progenity, Inc. (NASDAQ:PROG) shares fell 44.4% to $0.8275 in pre-market trading after the company reported pricing of $40 million public offering of common stock and warrants.
- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) fell 40% to $0.732 in pre-market trading. Sonnet BioTherapeutics shares jumped around 64% on Thursday on abnormally-high volume.
- Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) fell 11.6% to $15.23 in pre-market trading after dropping around 25% on Thursday. The company recently received an IND response from the FDA.
- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) fell 11% to $0.8050 in pre-market trading after gaining more than 4% on Thursday.
- HEXO Corp. (NYSE:HEXO) fell 10.9% to $2.85 in pre-market trading after the company announced a proposed public offering.
- Ensysce Biosciences, Inc. (NASDAQ:ENSC) fell 9.9% to $3.45 in pre-market trading after gaining over 22% on Thursday. Ensysce Biosciences recently reported a Q2 net loss of $1 million.
- Eros STX Global Corporation (NYSE:ESGC) shares fell 9.7% to $0.6413 in pre-market trading. Eros STX Global and Amazon.com Prime Video recently forged a multi-year first window output deal in South Africa.
- Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) fell 9.5% to $7.38 in pre-market trading. Sonoma Pharmaceuticals shares gained over 50% on Thursday in reaction to the launch of two new dental products.
- PharmaCyte Biotech, Inc. (NASDAQ:PMCB) shares fell 9.2% to $3.16 in pre-market trading. PharmaCyte Biotech shares fell around 65% on Thursday after the company announced a $70 million registered direct offering priced at-the-market under Nasdaq rules..
- AzurRx BioPharma, Inc. (NASDAQ:AZRX) shares fell 8.9% to $0.58 in pre-market trading. AzurRx BioPharma recently announced its Phase 2 MS1819 combination therapy trial met its primary and secondary outcome measure endpoints.
- Biocept, Inc. (NASDAQ:BIOC) shares fell 7.9% to $3.40 in pre-market trading. Biocept recently announced new data from a study assessing its cerebrospinal fluid assay, CNSide.
- NLS Pharmaceutics AG (NASDAQ:NLSP) fell 6.5% to $2.32 in pre-market trading. NLS Pharmaceutics recently received a Notice of Allowance from the U.S. Patent and Trademark Office for patent application No. 16/083,131.
- Ross Stores, Inc. (NASDAQ:ROST) fell 4.7% to $120.67 in pre-market trading. Ross Stores reported stronger-than-expected results for its second quarter. The company said its sees Q3 earnings of $0.61 to $0.69 per share.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.